Press Enter to search · ESC to close

Macro

BioNTech Buys FDA Priority Review Voucher for $205M

BioNTech has purchased a U.S. Food and Drug Administration priority review voucher for $205 million. The voucher allows its holder to expedite regulatory review of a single drug application. The transaction was reported on [date not given in material].

Share

Related News

新云社 share card
Long-press image above → Save to Photos / Share
Pitch us Feedback